Volume 4.19 | May 15

Mesenchymal Cell News 4.19, May 15, 2012
     In this issue: Publications Science News | Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
TOP STORY
Cardiac Repair Achieved by Bone Marrow Mesenchymal Stem Cells/Silk Fibroin/Hyaluronic Acid Patches in a Rat of Myocardial Infarction Model
Bone marrow mesenchymal stem cells/silk fibroin/hyaluronic acid patches were implanted into myocardial infarction rat hearts to investigate the efficacies of them on enhancing left ventricular remodeling and cardiac repair. [Biomaterials] Abstract

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Soluble CCL5 Derived from Bone Marrow-Derived Mesenchymal Stem Cells and Activated by Amyloid-Beta Ameliorates Alzheimer’s Disease in Mice by Recruiting Bone Marrow-Induced Microglia Immune Responses
Results suggest that the beneficial effects observed in Alzheimer’s disease mice after intracerebral bone marrow-derived mesenchymal stem cells transplantation may be explained by alternative microglia activation. [Stem Cells] Abstract

Genetic Modification of Mesenchymal Stem Cells to Overexpress CXCR4 and CXCR7 Does Not Improve the Homing and Therapeutic Potentials of These Cells in Experimental Acute Kidney Injury
CXCR4 and CXCR7 were separately and simultaneously overexpressed in BALB/c bone marrow mesenchymal stem cells by using a lentiviral vector system and the homing and renoprotective potentials of these cells were evaluated in a mouse model of cisplatin-induced acute kidney injury. [Stem Cells Dev] Abstract

Quantitative Approaches to Detect Donor and Passage Differences in Adipogenic Potential and Clonogenicity in Human Bone Marrow-Derived Mesenchymal Stem Cells
Researchers have shown that several quantitative assays can detect differences in multipotent stromal cell differentiation capacity, clonogenicity and cell size between donors and passages. [J Tissue Eng] Abstract

Hypoxia Impedes Hypertrophic Chondrogenesis of Human Multipotent Stromal Cells
Investigators focused on the effects of different oxygen tensions on the progression of hypertrophic differentiation of multipotent stromal cells. [J Tissue Eng] Abstract

Vascular Morphogenesis of Adipose-Derived Stem Cells Is Mediated by Heterotypic Cell-Cell Interactions
This study reports the novel finding that adipose-derived stromal/stem cells grown in monolayers in the presence of angiogenic cues are capable of self-assembling into complex, three-dimensional vascular structures. [J Tissue Eng]
Abstract

Long-Term In Vitro Expansion of Human Adipose-Derived Stem Cells Showed Low Risk of Tumourigenicity
The aim of this study was to investigate the effect of long-term in vitro expansion on human adipose-derived stem cells. [J Tissue Eng Regen Med] Abstract

Placenta- versus Bone Marrow-Derived Mesenchymal Cells for the Repair of Segmental Bone Defects in a Rabbit Model
Scientists explored tissue engineered bones (TEBs) constructed by placenta-derived mesenchymal stem cells, and compared their effect for the repair of critical-sized segmental osteoperiosteal defects with TEBs constructed with bone marrow-derived mesenchymal stem cells. [FEBS J] Abstract

Biologic and Immunomodulatory Properties of Mesenchymal Stromal Cells Derived from Human Pancreatic Islet
An in vitro analysis showed that pancreatic islet-derived mesenchymal stromal cells (MSC) have phenotypic, biologic and immunomodulatory characteristics similar, but not identical, to bone marrow-derived MSC. [Cytotherapy] Abstract

Watch the Video: Obtain Functional MSCs Xeno-Free with MesenCult-XF

SCIENCE NEWS

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy

INDUSTRY NEWS
Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell Therapies
Fibrocell Science, Inc. announced the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives Initiative in collaboration with researchers from a number of different universities across the U.S. [Fibrocell Science, Inc.] Press Release

New Teva Representative Joins Mesoblast Board of Directors

Global regenerative medicine company Mesoblast Limited announced the appointment of Dr Ben-Zion Weiner as a non-executive Director of Mesoblast, effective immediately. [Mesoblast Limited] Press Release
POLICY NEWS

A Global Standard for Peer Review
After winning the strong backing of the White House, Subra Suresh convened a meeting of 47 leaders of research funding agencies from 44 countries. At the conclusion of closed-door sessions, the group will issue the first-ever global statement on the principles of merit review. [National Science Foundation, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW World Stem Cells & Regenerative Medicine Congress 2013
March 18-21, 2013
Singapore, Singapore

Visit our events page to see a complete list of events in the mesenchymal cell community.

JOB OPPORTUNITIES

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)


Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)


Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)


Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)


Postdoctoral Position – Molecular Cell Biology (Weizmann Institute of Science) 


PhD Student (University of Liège) 


Postdoctoral Position (GENyO)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives | Events | Contact Us